Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
You may also be interested in...
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
ReNeuron's Cell Therapies Attract Fosun Pharma, A Leading Regenerative Medicines Developer
The UK cell therapy biotech ReNeuron has attracted the healthcare group, Fosun Pharma, which is building up a leading position in regenerative medicine, to develop and commercialize its products in China.
Medigene Takes Center Stage In Roivant's Latest 'Vant'
Roivant has launched its 16th Vant, called Cytovant, which hopes to be Asia's premier cell therapy company. It has inked a deal worth potentially $1bn with Germany's Medigene to develop TCR immunotherapies and a dendritic cell vaccine.